Will modulating this target change patient outcomes?

Causal evidence for a target is necessary but not sufficient. A gene that drives who gets a disease may have no bearing on how quickly it worsens in someone already diagnosed. Treating these as equivalent questions leads to misaligned trial designs, wrong primary endpoints, and phase II results that fail to reflect a real biological effect.

Trajecta™, 5 Prime Sciences' genomics-of-progression platform, separates incidence biology from progression biology at the genetic level. This distinction is embedded in the analysis from the start — not inferred after the fact.

Combined with Mendelian Randomization estimates of effect size and direction, this gives development teams a clear account of what an asset is likely to do: prevent onset, slow deterioration, or both. That account directly shapes patient selection criteria, primary endpoint choice, trial enrichment strategy, and the evidence base needed to justify a proof-of-concept investment.

This analysis is particularly relevant ahead of Phase II design decisions, in-licensing evaluations, or any program where the expected magnitude of clinical benefit needs to be grounded in human evidence rather than modelled from animal data.

80% of 5 Prime Sciences' partners return for subsequent analyses — reflecting the continued role this evidence plays as programs move through development.